Stock Analysis on Net

Allergan Inc. (NYSE:AGN.)

This company has been moved to the archive! The financial data has not been updated since February 19, 2015.

Income Statement 
Quarterly Data

Allergan Inc., consolidated income statement (quarterly data)

US$ in thousands

Microsoft Excel
3 months ended: Dec 31, 2014 Sep 30, 2014 Jun 30, 2014 Mar 31, 2014 Dec 31, 2013 Sep 30, 2013 Jun 30, 2013 Mar 31, 2013 Dec 31, 2012 Sep 30, 2012 Jun 30, 2012 Mar 31, 2012 Dec 31, 2011 Sep 30, 2011 Jun 30, 2011 Mar 31, 2011 Dec 31, 2010 Sep 30, 2010 Jun 30, 2010 Mar 31, 2010
Product net sales 1,889,000  1,790,700  1,827,300  1,619,100  1,659,600  1,528,400  1,577,000  1,432,500  1,484,600  1,391,100  1,467,400  1,365,700  1,382,800  1,311,100  1,400,400  1,252,800  1,290,100  1,192,000  1,231,700  1,105,800 
Cost of sales, excludes amortization of intangible assets (209,100) (206,600) (222,200) (204,500) (204,600) (192,200) (199,100) (199,900) (189,200) (188,800) (201,700) (195,800) (182,000) (188,100) (195,300) (183,300) (182,800) (177,700) (191,300) (170,200)
Amortization of intangible assets (27,600) (29,000) (28,000) (27,800) (28,200) (28,800) (29,000) (30,700) (33,200) (33,200) (33,300) (31,600) (32,000) (31,900) (31,200) (32,500) (32,500) (31,100) (37,300) (37,100)
Gross profit 1,652,300  1,555,100  1,577,100  1,386,800  1,426,800  1,307,400  1,348,900  1,201,900  1,262,200  1,169,100  1,232,400  1,138,300  1,168,800  1,091,100  1,173,900  1,037,000  1,074,800  983,200  1,003,100  898,500 
Other revenues 21,500  26,400  36,900  27,000  24,800  30,300  20,700  27,100  24,300  22,800  24,000  26,200  19,500  17,300  16,800  18,400  19,200  16,200  15,500  48,900 
Selling, general and administrative (745,000) (714,700) (718,900) (658,600) (715,400) (589,300) (609,900) (604,800) (557,900) (540,800) (584,600) (585,100) (551,900) (538,500) (566,700) (589,500) (527,500) (517,300) (499,000) (473,800)
Research and development (265,400) (288,500) (288,700) (349,000) (269,400) (257,600) (266,500) (248,800) (239,300) (293,300) (232,000) (225,000) (226,400) (221,300) (257,400) (197,700) (200,300) (194,000) (187,600) (222,700)
Legal settlement —  —  —  —  —  —  —  —  —  —  —  —  —  —  —  —  700  (609,900) —  — 
Impairment of intangible assets and related costs —  —  —  —  (11,400) —  —  —  (22,300) —  —  —  —  (4,300) (3,300) (16,100) —  (369,100) —  — 
Restructuring (charges) reversal (36,700) (185,500) 1,500  (24,300) (600) (600) —  (4,300) (1,000) (3,800) (900) —  —  100  (100) (4,600) 500  (100) (100) (600)
Operating income (loss) 626,700  392,800  607,900  381,900  454,800  490,200  493,200  371,100  466,000  354,000  438,900  354,400  410,000  344,400  363,200  247,500  367,400  (691,000) 331,900  250,300 
Interest income 1,500  2,000  2,400  1,800  1,700  1,500  2,000  1,600  1,900  1,900  1,700  1,200  1,300  1,800  1,500  2,300  3,200  1,600  1,200  1,300 
Interest expense (15,600) (18,400) (19,700) (15,700) (18,200) (19,400) (20,000) (17,400) (14,800) (15,900) (17,100) (15,800) (16,700) (15,200) (15,200) (24,700) (27,800) (20,400) (13,900) (16,600)
Other, net 21,300  43,000  (16,200) (6,400) 2,700  (15,500) 11,200  (8,700) (3,800) (9,200) 4,900  (15,000) (10,900) 25,800  (5,500) (9,900) (9,800) (17,900) 14,300  (3,000)
Non-operating income (expense) 7,200  26,600  (33,500) (20,300) (13,800) (33,400) (6,800) (24,500) (16,700) (23,200) (10,500) (29,600) (26,300) 12,400  (19,200) (32,300) (34,400) (36,700) 1,600  (18,300)
Earnings (loss) from continuing operations before income taxes 633,900  419,400  574,400  361,600  441,000  456,800  486,400  346,600  449,300  330,800  428,400  324,800  383,700  356,800  344,000  215,200  333,000  (727,700) 333,500  232,000 
(Provision) benefit for income taxes (91,300) (106,300) (156,000) (103,100) (128,400) (123,900) (132,400) (73,600) (124,100) (80,200) (132,000) (94,500) (104,000) (105,800) (95,400) (56,400) (69,900) 59,000  (92,000) (63,000)
Earnings (loss) from continuing operations 542,600  313,100  418,400  258,500  312,600  332,900  354,000  273,000  325,200  250,600  296,400  230,300  279,700  251,000  248,600  158,800  263,100  (668,700) 241,500  169,000 
Earnings from discontinued operations, net of applicable income tax —  —  —  —  1,000  5,500  7,200  400  —  —  —  —  —  —  —  —  —  —  —  — 
Gain (loss) on sale of discontinued operations, net of applicable income tax (3,500) 300  —  (600) (1,300) (37,600) —  (259,000) —  —  —  —  —  —  —  —  —  —  —  — 
Discontinued operations (3,500) 300  —  (600) (300) (32,100) 7,200  (258,600) —  —  —  —  —  —  —  —  —  —  —  — 
Net earnings (loss) 539,100  313,400  418,400  257,900  312,300  300,800  361,200  14,400  325,200  250,600  296,400  230,300  279,700  251,000  248,600  158,800  263,100  (668,700) 241,500  169,000 
Net earnings attributable to noncontrolling interest (1,900) (900) (1,200) (600) 600  (1,000) (1,300) (1,900) (1,000) (1,200) (1,000) (500) 100  (1,200) (2,000) (500) —  (1,800) (1,400) (1,100)
Net earnings (loss) attributable to Allergan, Inc. 537,200  312,500  417,200  257,300  312,900  299,800  359,900  12,500  324,200  249,400  295,400  229,800  279,800  249,800  246,600  158,300  263,100  (670,500) 240,100  167,900 

Based on: 10-K (reporting date: 2014-12-31), 10-Q (reporting date: 2014-09-30), 10-Q (reporting date: 2014-06-30), 10-Q (reporting date: 2014-03-31), 10-K (reporting date: 2013-12-31), 10-Q (reporting date: 2013-09-30), 10-Q (reporting date: 2013-06-30), 10-Q (reporting date: 2013-03-31), 10-K (reporting date: 2012-12-31), 10-Q (reporting date: 2012-09-30), 10-Q (reporting date: 2012-06-30), 10-Q (reporting date: 2012-03-31), 10-K (reporting date: 2011-12-31), 10-Q (reporting date: 2011-09-30), 10-Q (reporting date: 2011-06-30), 10-Q (reporting date: 2011-03-31), 10-K (reporting date: 2010-12-31), 10-Q (reporting date: 2010-09-30), 10-Q (reporting date: 2010-06-30), 10-Q (reporting date: 2010-03-31).

Income statement item Description The company
Product net sales Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise. Allergan Inc. product net sales decreased from Q2 2014 to Q3 2014 but then increased from Q3 2014 to Q4 2014 exceeding Q2 2014 level.
Operating income (loss) The net result for the period of deducting operating expenses from operating revenues. Allergan Inc. operating income (loss) decreased from Q2 2014 to Q3 2014 but then increased from Q3 2014 to Q4 2014 exceeding Q2 2014 level.
Earnings (loss) from continuing operations before income taxes Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. Allergan Inc. earnings (loss) from continuing operations before income taxes decreased from Q2 2014 to Q3 2014 but then increased from Q3 2014 to Q4 2014 exceeding Q2 2014 level.
Net earnings (loss) attributable to Allergan, Inc. The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Allergan Inc. net earnings (loss) attributable to Allergan, Inc. decreased from Q2 2014 to Q3 2014 but then increased from Q3 2014 to Q4 2014 exceeding Q2 2014 level.